A detailed history of Herold Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Herold Advisors, Inc. holds 5,001 shares of AMGN stock, worth $1.58 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
5,001
Previous 5,297 5.59%
Holding current value
$1.58 Million
Previous $1.71 Million 23.62%
% of portfolio
0.29%
Previous 0.38%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$258.78 - $328.31 $76,598 - $97,179
-296 Reduced 5.59%
5,001 $1.3 Million
Q3 2024

Nov 14, 2024

SELL
$309.38 - $337.38 $2,165 - $2,361
-7 Reduced 0.13%
5,297 $1.71 Million
Q2 2024

Jul 24, 2024

BUY
$262.75 - $319.31 $103,260 - $125,488
393 Added 8.0%
5,304 $1.66 Million
Q1 2024

May 10, 2024

BUY
$268.87 - $324.56 $816,558 - $985,688
3,037 Added 162.06%
4,911 $1.4 Million
Q4 2023

Feb 02, 2024

SELL
$255.7 - $288.46 $51,140 - $57,691
-200 Reduced 9.64%
1,874 $539,000
Q3 2023

Nov 08, 2023

BUY
$218.65 - $271.46 $154,585 - $191,922
707 Added 51.72%
2,074 $557,000
Q2 2023

Jul 14, 2023

BUY
$214.27 - $253.37 $59,352 - $70,183
277 Added 25.41%
1,367 $303,000
Q1 2023

Apr 19, 2023

BUY
$225.79 - $275.2 $72,252 - $88,064
320 Added 41.56%
1,090 $263,000
Q4 2022

Feb 14, 2023

BUY
$229.03 - $291.01 $176,353 - $224,077
770 New
770 $202,000
Q2 2022

Jul 15, 2022

SELL
$230.71 - $256.74 $169,110 - $188,190
-733 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$219.27 - $242.57 $160,724 - $177,803
733 New
733 $177,000
Q4 2021

Jan 20, 2022

SELL
$198.88 - $227.6 $145,580 - $166,603
-732 Closed
0 $0
Q3 2021

Nov 03, 2021

BUY
$212.27 - $248.7 $155,381 - $182,048
732 New
732 $155,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Herold Advisors, Inc. Portfolio

Follow Herold Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Herold Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Herold Advisors, Inc. with notifications on news.